Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) combined with conventional MRI can provide a whole body assessment of metastatic bone disease, improved lesion detection compared to other imaging techniques and a direct quantitative assessment of treatment response. In bone marrow, the presence of fat and bone trabeculae and their changing contributions with disease progression and response to treatment present unique challenges for data acquisition and image interpretation. This article discusses these challenges and reviews the potential of DW-MRI to provide a biomarker of response in metastatic bone disease.
With MRI, hardware and software advances have meant that Diffusion Weighted techniques (DW-MRI), initially successfully implemented in neurological applications, are now used for body imaging [7] . In bone, DW-MRI has potential to provide new and previously unobtainable quantitative measures of response of metastatic lesions. Further, it allows fusion of functional data from whole body acquisitions with the corresponding anatomical data whilst avoiding radiation exposure and intravenous contrast agents ( Figure 1 ). However, imaging the bony skeleton in this way presents unique challenges in order to achieve robust and meaningful results. This article reviews basic principles and techniques for implementing DW-MRI in bone and discusses the unique histology of bone marrow and its implications for DW-MRI interpretation, addressing its clinical strengths and limitations.
Basic concepts of Diffusion Weighted MRI
To achieve diffusion weighting in MRI, two complimentary motion sensitising gradients are incorporated into the imaging sequence. For stationary molecules, the effects of these gradients are reciprocal and there is no signal change. For water molecules that are moving, loss in MR signal intensity with the application of diffusion sensitising gradients provides a measure of water diffusion. The loss in MR signal intensity in relation to the applied gradient may be quantified and expressed as an apparent diffusion coefficient (ADC). Thus DW-MRI can quantify image contrast based on diffusion properties of water within tissues at a cellular level. In a highly cellular tissue, extracellular water would not be able to diffuse far during the MR observation period without being blocked by structural interfaces such as cell membranes; this would lead to a short diffusional path and a reduced ADC. Soft tissue tumours which consist of tightly packed cells therefore appear as areas of restricted diffusion relative to normal soft tissues [19] .
The motion sensitizing gradients used to provide diffusion weighting can be varied in terms of their amplitude, duration and spacing to provide different degrees of diffusion weighting. The variation of these gradient parameters is represented by a "b" value which is measured in s/mm 2 . Use of multiple b values enables a plot of signal intensity against b value: the slope of this log plot provides a pixel by pixel quantitation of the ADC which is measured in mm 2 (range 0-100 s/mm 2 ) interrogate large diffusion distances and are therefore sensitive to flow in blood vessels. Large b values (>100-1000 s/mm 2 ) detect small diffusion distances postulated to be related to extracellular space distances and therefore thought to be directly related to cell packing/cellularity. The inverse correlation between cell density and ADC (using b values up to 1000 s/mm 2 ) has been extensively described [15;33;57;59] . This is further supported by indirect evidence that choline, a marker of cell turnover is inversely correlated with ADC in glioma [16] .
However cellularity is not the sole factor influencing ADC and the relationship between cellularity and ADC has not been so impressive in other cell types [15] particularly renal tumours [56] . Other factors may influence ADC, for example cellular architecture, cell size, viscosity of cytoplasm, bulk flow in capillaries and active transport have been variously implicated in small studies, but their effect remains to be proven. Theoretically, with very large b values (>4000 s/mm 2 ) it is possible to interrogate the movement of intracellular water protons, but at a practical level signals obtained with these large b values are very low and long TEs are required resulting in low signal-to-noise ratios so that with current imaging methods the measurement is not robust. This can to some extent be overcome but at the expense of resolution or increased imaging time due to the use of multiple averages [65] . Volume fractions of slow-diffusing and fast-diffusing water populations extracted from simple biexponential analysis have been shown in some cases to deviate significantly from known ratios of intracellular and extracellular water. This may well be due to differing T2 relaxation times of compartments. Alternative explanations are the presence of more than two compartments, exchange between compartments, anisotropy and varying restriction of intracellular water by cell membranes [50] . However evidence from preclinical brain studies indicates that compartmentalisation is not an essential feature of biexponential decay as it persists despite presence of disintegrated cell membranes on electron-microscopy [54] . ADC may therefore be used clinically as a measure of cellularity but its value in separating intra or extracellular water
is not yet clinically viable.
In response to treatment, the increased free water within a tumour manifests as an increase in Studies of DW-MRI as a marker of treatment response have traditionally compared a mean tumour ADC encompassing the whole volume of tumour before and after treatment. However, to take into account heterogeneity within human tumours, Moffat et al [37] investigated the functional diffusion map (fDM). This allows spatial, voxel by voxel tracking of changes in water diffusion values within tumours using digital registration techniques. Work on patients with gliomas revealed that the fDM could be used to stratify patients as responsive or nonresponsive at 3 weeks and the fDM was proposed as a potential predictive tumour imaging biomarker for early stratification of tumour response. Preclinical models which correlate fDM changes with survival and cell kill also support this [36;37] . The exact mechanisms by which a response to therapy causes an increase in ADC are poorly understood and are likely to be tumour type, mode of therapeutic action and timing dependant. Apoptosis leads to cell shrinkage and increased mobility of extracellular water. Necrosis also has been shown to cause a rise in ADC in the absence of apoptosis. The current wisdom is that cell shrinkage in apoptosis, and breakdown of plasma membranes in necrosis [38] are the main factors that result in an increased ADC tumours responding to treatment.
Unfortunately these patterns of ADC change are not directly applicable to metastatic bone disease.
Diffusion Weighted MRI in bone
i.
Technical Considerations
The key factors to successful imaging of the bony skeleton with MRI are speed and coverage.
Although bone is less prone to bulk motion, short scan times with high signal-to-noise ratios and resolution with minimal geometric distortion are highly desirable. signal-to-noise ratio of these fast imaging methods can be improved by adopting a "freebreathing" approach over several minutes and increasing the number of signal averages acquired. Thin partitions of 4-5mm improve spatial resolution and allow multiplanar reformats.
Line scan diffusion imaging was developed to overcome motion artefacts but produces low spatial resolution perpendicular to the readout and has low signal-to-noise ratio [34] . With diffusion-weighted sequences, it is reported that motion artefact is not a problem with a free breathing technique due to the speed of the diffusion sensitising gradients which results in effects of such bulk motion being averaged out [58] . Currently non breath hold spin echo EPI combined with fat suppression is a useful all purpose sequence.
Susceptibility differences between neighbouring tissues produce inhomogeneities in the magnetic field and subsequent image distortion. This can be minimised by manual shimming [66] . Reducing the echo time (TE) with parallel imaging is also beneficial as it allows less time for dephasing [24] . The susceptibility artefacts tend to be more severe with increasing b value and any image distortion will cause errors in ADC calculations. Geometric distortions can be reduced by using high receiver bandwidth, large field of view, acquiring thick slices and using a radiofrequency coil of cylindrical geometry such as a body coil.
Eddy currents are induced when diffusion gradient pulses are switched rapidly. These result in magnetic gradients that combine with the imaging gradient pulses to produce geometric distortions proportional to the gradient pulses that therefore vary between different b values.
Also, mismatch between the applied and effective gradients cause variations in voxel size.
Variability in distortion and voxel size on individual diffusion sensitized images used for generating ADC maps this leads to inaccuracies in calculated ADCs. Eddy current artefacts may be reduced by refocusing the signal twice with the use of four diffusion sensitising gradients [46] ii Tissue Structure Considerations
The unique structure of cortical bone and bone marrow presents particular challenges both in data acquisition and in image interpretation. Cortical bone consists of a calcified matrix with very little free water for diffusion. Bone marrow has a high fat content where paucity of free water protons causes profound diffusion restriction. The water fraction of vertebral marrow in an adult male can be as low as 48% and is affected by factors such as age which influences the proportion of hematopoietic to fatty marrow [20] . In order to achieve optimal image contrast for bony lesions therefore, judicious choice of parameters for diffusion weighting is essential. haematopoietically active marrow has more intracellular water and adjacent free water than less active marrow. This seems to make room for more molecular diffusion in cellular than less cellular marrow [41] . In keeping with this T2 relaxation was consistently elevated in bone marrow of 7 hypercellular patients with leukaemia relative to the bone marrow of normal volunteers [1] . However it is likely that there is a point at which increased cellularity begins to restrict diffusion. This is described in a patient following granulocyte colony stimulating factor (G-CSF) [2] . Differentiation of diffuse pathological marrow from normal hypercellular marrow in young adults or patients with hypercellular marrow related to treatment can be more Sclerosis as part of the osteoblastic healing process also has potential to cause a fall in ADC.
These conflicting processes necessitate special consideration when interpreting ADC changes following treatment. At the outset quantifying changes in the fraction of fat within lesions is critically important. This can be done using subtraction of sequences which image fat and water in and out of phase to give fat only images. Alternatively, histograms of ADC values within a lesion can be generated and changes in the number of pixels representing normal fatty marrow (ADC values for normal marrow have already been established [41] can be measured ( Figure   6 ). Segmentation of ADC maps to characterise tissue populations has been used in the brain
[21] but has not been explored for bony lesions.
Identifying and quantifying the component contributing to the osteoblastic healing process is essential in osteoblastic metastases but is not necessary in all tumour types e.g. myeloma.
Isolating and measuring the osteoblastic process by MR alone is challenging because the relaxation time of sclerotic lesions is very short and these lesions return very little signal on conventional imaging. Newer techniques such as ultra short TE (UTE) sequences which enable measurement of signal from cortical bone [47] 
Comparison of DW-MRI with other imaging for evaluating metastatic bone disease
Over the last several decades 99m Tc -MDP bone scintigraphy has been used as a robust albeit non quantitative indicator of response assessment of bone metastases to treatment. However, false positives frequently secondary to degenerative/inflammatory change occur. Increased uptake at 3 months can also be due to osteoblastic response mimicking progressive disease (the flare response) with follow up 99m Tc-MDP bone scintigraphy at 6 months being required to Specificity problems with 18 
Future utility in clinical trials
With time to progression and progression free survival frequently used as intermediate endpoints for overall survival in clinical trials it is critical that the methodology for defining progressive disease in imaging assessment of bone metastases is clear. Variation in assessment can have a significant impact on progression free survival endpoints [14] .
Conventional CT and 99m Tc-MDP bone scintigraphy at 3 months post treatment can be misleading because of the flare response. Even within the first 6 months of treatment these modalities are unreliable as intermediate endpoints. This is of particular importance in trials of castrate resistant prostate cancer where, in our experience, bone metastases are present in 80% of patients with bone as the only site of visible disease in a third of cases.
The use of DW-MRI in the clinical trial setting for assessing treatment response of bone metastases is in its infancy. Case studies of patients with prostatic bone metastases, marrow disorders and leukaemia treated with docetaxol using a whole body DW-MRI have shown possible treatment related changes in keeping with clinical and haematological/marrow response respectively [2;28] . In our experience these changes are not always reliably demonstrated, but further technical refinements are likely to improve this.
Conclusion
As experience of DW-MRI of metastatic and myeloma bone disease grows it is apparent that detailed attention to technique and data interpretation is required. The need for optimal imaging parameters whilst minimising artefacts pushes current system hardware to its limits. In contrast to soft tissue tumours, bone metastases are conspicuous as foci of increased diffusivity relative to normal fatty marrow. ADC changes must be interpreted in light of the shifting relationship between fat, cellularity and bony trabecular matrix as tumours respond to/ progress on treatment. Of course, these relationships are also dependant on tumour type, timing and therapy. DW-MRI can be applied as a whole body technique and the combination of functional and anatomical data is highly informative.
The utility of DW-MRI in metastatic and myeloma bone disease needs to be developed further within a framework of biomarker development. Preclinical studies are of paramount importance for histopathological validation as in clinical studies bone biopsy is rarely feasible and validation relies on indirect markers of disease activity. Protocols and methods of analysis appropriate to bone require consensus agreement. Reproducibility and repeatability specific to imaging bone need to be established. Also, the degree of heterogeneity between and within tumours needs documenting as it is will affect powering of future studies and impacts on the potential use/success of any biomarker [43] . Only when this groundwork is done can we progress to clinical trials with a robust biomarker of response assessment in bone. DW-MRI is becoming established as a powerful tool in oncology and its potential in imaging malignant bone disease should be exploited. Success relies on rigorous and systematic development within consensus groups.
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